Most β3-AR agonists identified thus far exhibit off-target effects on other β-ARs, leading to side effects such as cardiovascular risks (Hainer, 2016), potentially limiting their clinical application in obesity control. This evidence concerns the gene ADRB3 and obesity disorder.